Reflecting on 2025: Key Milestones for Our Community
As we look back on 2025, we’re proud to share an overview of the significant milestones that shaped the year for our community. This year brought important progress across our core conditions: heterozygous familial hypercholesterolaemia (HeFH), homozygous familial hypercholesterolaemia (HoFH), elevated Lp(a), and familial chylomicronaemia syndrome (FCS). We’ve compiled a document that tracks the major regulatory updates, clinical trial results, events, and community projects from the […]
Read more